Crinetics Pharmaceuticals Inc. (CRNX), which reported positive results from its phase III PATHFNDR-1 study last September, is expected to report phase III PATHFNDR-2 study topline data this quarter.
The company's lead drug candidate is Paltusotine, a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist designed for the treatment of acromegaly.
Acromegaly is a rare disorder caused by benign pituitary tumor that secretes excess growth hormone, which in turn leads to excess secretion of insulin-like growth factor-1 (IGF-1). This disorder is characterized by bone and cartilage overgrowth, organ enlargement, changes in glucose and lipid metabolism, abnormal growth of hands and feet, and alteration of facial features. Novartis' Sandostatin, Ipsen Biopharmaceuticals' Somatuline, Pfizer's Somavert and Amryt Pharma's Mycapssa are some of the FDA-approved treatments for acromegaly.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.